ReviewFrontiers in neurology2025
Wernicke encephalopathy: a mini review of the clinical spectrum, atypical manifestations, and diagnostic challenges.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Wernicke Encephalopathy Secondary to Cannabinoid Hyperemesis Syndrome in a 15-Year-Old Male Patient: A Case Report.Cureus · 2026Article
- Article
- Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.Current neurology and neuroscience reports · 2026Review
- Association of thiamine supplementation with 30-day mortality among ICU patients with sepsis-associated delirium.Scientific reports · 2026Article
- Fulminant cardiovascular collapse after acute pancreatitis: a case report of non-alcoholic Shoshin beriberi and literature review.AME case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wernicke encephalopathy (WE) is a severe neurological disorder caused by thiamine (vitamin B1) deficiency. Though often associated with chronic alcohol abuse, it can also arise from other conditions that impair thiamine intake or absorption. The classic triad of symptoms includes ophthalmoplegia, an abnormal mental state, and gait ataxia, although these may not be present in all patients, leading to underdiagnosis and undertreatment. Methods: This mini review synthesizes data from clinical studies, autopsy reports, and imaging findings to assess the prevalence, diagnostic challenges, and treatment protocols for WE. It examines the role of various etiological factors, the presentation of atypical symptoms, and the utility of diagnostic tools such as magnetic resonance imaging (MRI) and vitamin B1 assays. Results: Autopsy studies report a prevalence of WE that ranges from 0.4 to 2.8%, with most patients experiencing alcohol addiction or having other alcohol use disorders. The diagnosis of WE is primarily clinical, based on the Caine criteria in which a person must display at least two of the three classic symptoms or evidence of nutritional deficiency. MRI is a valuable tool for diagnosing WE, typically showing symmetric T2/FLAIR hyperintense signals in specific brain regions. Treatment involves prompt thiamine replacement, with intravenous administration being the most effective method to ensure adequate brain uptake. Conclusion: WE remains a challenging condition to diagnose due to its variable presentations and the potential for atypical symptoms. Early recognition and treatment with thiamine are crucial to prevent irreversible neurological damage or death. There is a need for clear diagnostic and treatment guidelines to improve the management of WE and reduce the risk of underdiagnosis and undertreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.